AKTX Latest Press Releases

-- October 13, 2026 --

Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering Globe Newswire 9:01 AM

-- October 1, 2026 --

Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers Globe Newswire 8:25 AM

-- September 8, 2026 --

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums Globe Newswire 9:15 AM

-- August 27, 2026 --

JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs ACCESS Newswire 9:01 AM

Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference Globe Newswire 9:01 AM

-- August 18, 2026 --

Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy Globe Newswire 8:53 AM

-- August 13, 2026 --

Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform Globe Newswire 4:15 PM

-- August 4, 2026 --

Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation Globe Newswire 8:50 AM

-- July 22, 2026 --

Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity Globe Newswire 8:40 AM

-- July 21, 2026 --

Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics Globe Newswire 7:05 AM

-- July 7, 2026 --

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board Globe Newswire 8:55 AM

-- June 29, 2026 --

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones Globe Newswire 8:45 AM

-- June 4, 2026 --

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026 Globe Newswire 9:30 AM

-- May 28, 2026 --

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor "What This Means" Segment Following ASCO Abstract Acceptance Globe Newswire 9:17 AM

-- May 21, 2026 --

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models Globe Newswire 5:01 PM

Akari Therapeutics Announces $5.5 Million Private Placement Offering Globe Newswire 8:30 AM

-- May 18, 2026 --

Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase Globe Newswire 9:05 AM

Market Data Delayed 15 Minutes